RGIN (Regenicin) E10: $-0.01 (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin E10?

Regenicin RGIN -99.00% E10 is $-0.01 as of Mar. 2023.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regenicin's adjusted earnings per share data for the three months ended in Mar. 2023 was $-0.002. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.01 for the trailing ten years ended in Mar. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-02), Regenicin's current stock price is $0.0001. Regenicin's E10 for the quarter that ended in Mar. 2023 was $-0.01. Regenicin's Shiller PE Ratio of today is .


Regenicin  (OTCPK:RGIN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Regenicin E10 Related Terms


Regenicin E10 Historical Data

* Premium members only.

The historical data trend for Regenicin's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin E10 Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.03 0.00 -0.02 -0.01

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

RGIN vs NOVNQ, TMBRQ, RGRX: E10 Comparison

For the Biotechnology subindustry, Regenicin's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regenicin's Shiller PE Ratio falls into.



Regenicin E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regenicin's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.002/301.8360*301.8360
=-0.002

Current CPI (Mar. 2023) = 301.8360.

Regenicin Quarterly Data

per share eps CPI Adj_EPS
201306 -0.010 233.504 -0.013
201309 -0.030 234.149 -0.039
201312 0.000 233.049 0.000
201403 -0.003 236.293 -0.004
201406 -0.002 238.343 -0.003
201409 0.020 238.031 0.025
201412 0.010 234.812 0.013
201503 0.010 236.119 0.013
201506 -0.003 238.638 -0.004
201509 -0.019 237.945 -0.024
201512 -0.002 236.525 -0.003
201603 -0.002 238.132 -0.003
201606 -0.002 241.018 -0.003
201609 0.000 241.428 0.000
201612 -0.002 241.432 -0.003
201703 -0.002 243.801 -0.002
201706 -0.001 244.955 -0.001
201709 -0.005 246.819 -0.006
201712 -0.001 246.524 -0.001
201803 -0.002 249.554 -0.002
201806 -0.001 251.989 -0.001
201809 0.000 252.439 0.000
201812 -0.002 251.233 -0.002
201903 -0.001 254.202 -0.001
201906 -0.001 256.143 -0.001
201909 -0.006 256.759 -0.007
201912 -0.001 256.974 -0.001
202003 -0.001 258.115 -0.001
202006 -0.001 257.797 -0.001
202009 0.000 260.280 0.000
202012 -0.001 260.474 -0.001
202103 -0.002 264.877 -0.002
202106 -0.001 271.696 -0.001
202109 -0.001 274.310 -0.001
202112 -0.001 278.802 -0.001
202203 -0.001 287.504 -0.001
202206 -0.001 296.311 -0.001
202209 -0.001 296.808 -0.001
202212 -0.002 296.797 -0.002
202303 -0.002 301.836 -0.002

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.01 mean?
Regenicin (RGIN) has a E10 of $-0.01 as of Mar. 2023. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regenicin and its competitors.
Is Regenicin's E10 too high?
Regenicin's current E10 is $-0.01.
How does Regenicin's E10 compare to NOVNQ and TMBRQ?
Regenicin's E10 of $-0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regenicin and its competitors. Regenicin's current E10 is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current E10 of $-0.01. The current E10 is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Regenicin (RGIN), the current E10 is $-0.01 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.